Active Ingredients: Exploring the Key Factors Affecting the Rising Cost of Developing New Drugs* | Zendy

Sarah J. Fossett | Zendy; Phanindra V. Wunnava | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Active Ingredients: Exploring the Key Factors Affecting the Rising Cost of Developing New Drugs*

Author(s) -

Sarah J. Fossett,

Phanindra V. Wunnava

Publication year - 2019

Publication title -

international journal of health sciences (ijhs)

Language(s) - English

Resource type - Journals

eISSN - 2372-5060

pISSN - 2372-5079

DOI - 10.15640/ijhs.v7n3a1

Subject(s) - blame , incentive , medical prescription , business , argument (complex analysis) , public economics , pharmaceutical industry , drug , compensation (psychology) , order (exchange) , drug development , economics , pharmacology , finance , medicine , market economy , psychiatry , psychoanalysis , psychology

What makes prescription drugs cost so much? The media and Congress say it is corporate greed, while pharmaceutical firms blame federal regulations and an expensive drug development process. This study focuses on R & D (RD both CEO compensation and phase II development are positively correlated with R & D expenditures. However, we have reason to believe that CEO compensation is more of an indicator of business strategy than greed. Finally, this study proposes possible research extensions for continued study.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research